What Ossianix does

Ossianix is a privately held biotechnology company founded in 2012 by Frank S. Walsh, Corey Goodman and J. Lynn Rutkowski, focused on solving the blood-brain barrier delivery problem that has historically blocked large-molecule therapeutics from reaching the brain at clinically meaningful concentrations. The company's core technology is the TXP1 Brain-Selective Shuttle, a deimmunised single-domain VNAR (Variable New Antigen Receptor) antibody scaffold derived from sharks that targets transferrin receptor 1 (TfR1) to achieve receptor-mediated transcytosis across the BBB. In non-human primate studies, TXP1 has demonstrated greater than 40-fold improvement in brain delivery of therapeutics, greater than 30-fold increase in hippocampus levels versus control, 4 nM brain concentration 20 hours post-dose at 1.35 mg/kg, and prolonged brain exposure with no off-target accumulation in liver, spleen, lung, kidney or muscle. The product portfolio includes a brain-penetrant CD20 antibody lead candidate for multiple sclerosis and CNS lymphoma, a TrkB agonist antibody for Parkinson's disease, a partnered AT-04 pan-amyloid removal program with Attralus, and an earlier-generation TXB2 shuttle plus a mouse surrogate tool for preclinical proof-of-concept work.

Ossianix monetizes its platform through a licensing and research-collaboration business model aimed at pharmaceutical partners developing CNS and metabolic therapeutics. Named partners include Lundbeck (strategic research collaboration since 2014 with a license for CNS products and milestone payments), Novo Nordisk (2018 research and option agreement for BBB delivery in diabetes/metabolic disease) and Attralus (2022 option and license agreement for AT-04 in neurodegeneration). Revenue is supplemented by non-dilutive grant funding from organizations including The Michael J. Fox Foundation (US$1.26 million in January 2025), The ALS Association, and the Pennsylvania Wolf Administration's COVID-19 Vaccines program. Pricing is not publicly disclosed and is negotiated contract-by-contract. GTM is enterprise field sales: partnering with pharma business development and licensing teams, supported by peer-reviewed publication output and scientific conference presentations rather than paid marketing.

The company is dually headquartered with its principal office at the University City Science Center in Philadelphia, Pennsylvania and research laboratories at the Stevenage Bioscience Catalyst in Hertfordshire, UK. Legal entity is Ossianix Inc. (Delaware), with UK operations conducted as a branch/representative office. The company is independently operated, not publicly listed, and has not been acquired; prior capital structure reflects a convertible promissory note from Lundbeck, early BioAdvance and ALS Association funding, and grant inflows. Headcount is small (10-15 employees) and the leadership team is concentrated around the three founder-scientists plus a COO, a VP of Research, and a board drawn from former senior R&D leadership at Wyeth, Pfizer and GSK.

Name

Ossianix

Legal name

Ossianix Inc.

Website

https://ossianix.co.uk

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Ossianix is a privately held biotechnology company developing a deimmunised shark-derived VNAR antibody shuttle (TXP1) that delivers biologic therapeutics across the blood-brain barrier by greater than 40-fold, licensed to pharmaceutical partners developing CNS and metabolic disease drugs.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Delivery / Blood-Brain Barrier Platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Blood-brain barrier delivery
• VNAR antibody platform
• CNS drug delivery
• Single domain antibodies
• Biotherapeutics licensing

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Licensing and Royalty Revenue: Ossianix licenses its proprietary BBB delivery technology to pharmaceutical companies. Partners gain access to the patented VNAR brain shuttle platform for developing CNS therapeutics, with Ossianix receiving milestone payments and potential royalties on approved products.
2. Research Collaboration Funding: Strategic research collaborations with pharma companies (Lundbeck, Novo Nordisk) where partners fund research programs with development and regulatory milestones. Includes equity investments from partners.
3. Non-Dilutive Grant Funding: Awards and grants from foundations and government programs (Michael J. Fox Foundation, Pennsylvania Wolf Administration COVID-19 program, The ALS Association) to support specific research programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Ossianix develops and licenses the TXP1 Brain-Selective Shuttle, a proprietary platform based on deimmunised shark VNAR antibodies that target TfR1 to deliver therapeutic payloads across the blood-brain barrier. The company earns revenue by licensing this BBB delivery technology to pharmaceutical companies for use with their CNS therapeutic candidates, by conducting funded research collaborations, and by progressing a small internal pipeline of brain-penetrant antibodies in indications such as multiple sclerosis and Parkinson's disease.

Product overview

Ossianix is a privately held single domain antibody company with a proprietary brain-selective shuttle platform based on deimmunised VNAR antibodies originating from sharks. The core technology consists of the TXP1 Brain Shuttle, the most advanced platform ready for clinical translation, which enables delivery of therapeutic payloads across the blood-brain barrier by >40-fold through receptor-mediated transcytosis targeting TfR1. The company's product portfolio includes therapeutic candidates developed internally (brain-penetrant CD20 antibody for multiple sclerosis/CNS lymphoma, TrkB agonist antibody for Parkinson's disease) as well as partnered programs (AT-04 with Attralus for neurodegenerative disorders). TXB2 represents the first-generation shuttle, while the surrogate mouse shuttle supports preclinical proof-of-concept studies.

Differentiator

Problem solved

Functional benefit

Products and services

• TXP1 Brain Shuttle A brain-selective shuttle based on the deimmunised VNAR antibody scaffold that targets TfR1 (Transferrin Receptor 1) for efficient receptor-mediated transcytosis across the blood-brain barrier, delivering therapeutic payloads to the brain by greater than 40-fold. Licensed to pharmaceutical partners for integration with their CNS biologic candidates.
• VNAR Antibody Platform Single domain VNAR (Variable New Antigen Receptor) antibodies derived from sharks, used as the foundational scaffold for Ossianix's brain delivery technology. The small VNAR format with extended CDR3 loops binds epitopes that conventional antibodies cannot reach.
• TXP1 Mouse Brain-Selective Shuttle (Surrogate) Optimal mouse brain-selective shuttle surrogate for mouse models, designed to support easy progression through preclinical efficacy proof-of-concept stages.
• Brain-Penetrant CD20 Antibody Lead internal product candidate: a brain-penetrant CD20 antibody in bispecific VNAR format, comprising Rituxan fused to the TXP1 shuttle, for multiple sclerosis and CNS lymphoma.
• TrkB Agonist Antibody Neuroprotective antibody candidate with potential to modify disease progression in Parkinson's disease, delivered across the blood-brain barrier using the TXP1 Brain Shuttle.
• AT-04 Pan-Amyloid Removal Therapeutic Pan-amyloid removal (PAR) peptibody developed by Attralus, fused with PAR-peptide and the IgG1 Fc, delivered to the brain using Ossianix's TXP1 Brain Shuttle for neurodegenerative disorders such as Alzheimer's disease. Subject of the Ossianix-Attralus option and license agreement.
• TXB2 Shuttle First-generation VNAR brain shuttle targeting the transferrin receptor, demonstrating high-level CNS delivery in mouse models with long plasma pharmacokinetics and no safety issues. Predecessor to the TXP1 platform.

Quantifiable outcome

• >40-fold improvement in brain delivery of therapeutics in primates
• +3 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• AttraluscoreTechnology or Integration · 17 November 2022Option and license agreement for using TXP1 Brain Shuttle to enhance targeted delivery of AT-04 pan-amyloid removal therapeutic candidate across the BBB for neurodegenerative disorders such as Alzheimer's disease.
• Novo NordiskcoreStrategic or Co-development Partner · 4 September 2018Research collaboration and option agreement for delivering therapeutic molecules across the BBB for diabetes and other metabolic diseases. Ossianix provides its patented VNAR antibodies to deliver Novo Nordisk therapeutic agents.
• LundbeckflagshipStrategic or Co-development Partner · 13 January 2014Ossianix and Lundbeck entered a strategic research collaboration in 2014 (expanded in 2014 and again subsequently) focusing on VNAR antagonists for pain treatment and BBB delivery technology for CNS disorders. Lundbeck has taken a license for development of CNS products and provided milestone payments. Financial terms not disclosed.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Vivoryon Therapeutics: European clinical-stage biotech developing small-molecule and biological therapies for Alzheimer's disease, including approaches that benefit from improved brain exposure. Comparable as a CNS-focused company targeting amyloid/neurodegeneration similar to Ossianix's AT-04 partnered program.
• Alnylam Pharmaceuticals: Commercial-stage RNAi therapeutics company actively developing CNS-delivery programs (including conjugates targeting transferrin receptor). Comparable to Ossianix on the underlying problem of delivering large biologics across the BBB.
• Vigil Neuroscience: Clinical-stage CNS biotech focused on microglial biology and neurodegenerative disease. Comparable as a small, focused CNS biologics company pursuing high-unmet-need neurological indications in a similar deal-and-partnership model.

Direct peers

• JCR Pharmaceuticals: Japanese specialty pharma that has built a BBB delivery platform around transferrin-receptor targeting (J-Brain Cargo) and is actively out-licensing and co-developing CNS biologics. Closest mechanism-level competitor to TXP1 outside the US.
• BioArctic: Swedish biotech developing brain-penetrant antibody therapies for neurodegeneration, with a major partnership with Eisai (Leqembi). Comparable to Ossianix as a smaller CNS antibody specialist leveraging brain-targeted delivery for neurodegenerative disease.
• Denali Therapeutics: Clinical-stage biotech with a leading TfR-based BBB delivery platform (OTV) and multiple partnered CNS programs. Directly comparable to Ossianix on mechanism (receptor-mediated transcytosis) and target indication space, but with substantially more capital and clinical progress.
• Prothena Corporation: Clinical-stage biotech developing antibody-based therapeutics for neurodegenerative diseases (e.g., Alzheimer's, Parkinson's). Comparable as a CNS biologics company addressing the same neurological indications as Ossianix's partnered and internal programs.

Others

• Arvinas: Clinical-stage biotech engineering novel protein-based modalities (PROTAC degraders) for CNS and other indications. Comparable as a protein-engineering platform company monetizing its discovery engine via partnerships with major pharma.

Broad incumbents

• Ionis Pharmaceuticals: Established CNS-focused RNA-targeted therapeutics company with multiple programs in neurological disease. Comparable in targeting CNS indications with novel molecular approaches, though using antisense oligonucleotides rather than antibody-based brain delivery.
• Roche (Brainshuttle): Operates a transferrin-receptor-based Brainshuttle platform within its CNS portfolio, with clinical-stage assets. A large-pharma incumbent whose in-house BBB delivery technology competes head-to-head with Ossianix's TXP1 for partnership economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ossianix